Abstract
In the current study, dually modified retrograded acetylated corn starch was prepared with improved physicochemical properties than its native form. The modified starch was utilized as a polymer for colonic targeted direct compressible tablets with budesonide as a model drug. In vitro release study showed the formulation exhibited pH dependent release profile with 81.38% drug release within the entire ileocolonic region. This suggests a significant improvement in the release profile over currently available colon targeted oral budesonide formulations that release most of the drug before the large intestine. In the dual modified starch, retrogradation resulted in the conversion of starch granules into small crystallites which blocked the void spaces of the polymer network and thereby retarded its disintegration. Esterification enhanced hydrophobicity, decreased swelling power and surface porosity of the starch. The direct compressible budesonide tablet using retrograded starch acetate polymer can therefore be a novel treatment option for ileocolonic irritable bowel disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
